• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Establishing a Dose-Response Relationship for Lurasidone in Acute Schizophrenia

Establishing a Dose-Response Relationship for Lurasidone in Acute Schizophrenia

November 5, 2021
Garrett Rossi, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Garrett Rossi, MD. Dr. Rossi has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Srisurapanont M et al, Sci Rep 2021:11(1):5571


STUDY TYPE: Network meta-analysis


Lurasidone is FDA approved in schizophrenia, but we lack good evidence to guide its dosage. This study compared the efficacy, safety, and acceptability of lurasidone at different doses to establish a dose-response relationship for its therapeutic and adverse effects.


The study was a network meta-analysis of 10 randomized controlled trials with a total of 3336 adult patients with acute schizophrenia. The selected trials used fixed-dose lurasidone and lasted 4–16 weeks. Studies with a crossover design or flexible dosing were excluded. The primary outcomes were overall reduction in psychotic symptoms as measured by the Positive and Negative Syndrome Scale (PANSS) and all-cause dropout rates. These data allowed the investigators to compare 10 independent treatments at various doses of lurasidone (20, 40, 80, 120, and 160 mg/day) against a placebo or four comparator antipsychotics.


The analysis found that all doses except the 20 mg/day were effective in acute schizophrenia. The highest dose (160 mg/day) outperformed all of the lower doses on the primary outcome of improvement in the PANSS. The “effective dose 50,” which estimates the dose that produces the desired effect in at least half the population, was at least 80 mg/day.


An interesting finding arose when the investigators attempted to find the maximum effective dose by graphing the results. The graphs for psychotic symptoms, negative symptoms, and depressive symptoms continued to rise without plateauing up to the maximum approved dose of 160 mg/day, suggesting that lurasidone’s maximum effective dose may be higher than that. Most side effects rose in concert with the dose, particularly sedation and EPS, but all-cause dropouts were similar across the 40–160 mg/day dose range. This suggests that the tolerability problems may be outweighed by the benefits in the higher dose range.


TCPR’S Take
Lurasidone requires higher dosing to reach maximum efficacy in schizophrenia, up to the official maximum of 160 mg/day and possibly beyond that. High doses did not lead to higher dropout rates, but in our experience, one particular side effect is lessened with a slow titration: akathisia.

General Psychiatry
KEYWORDS antipsychotics dose-response dosing lurasidone schizophrenia
Garrett Rossi, MD.

Management of Depression and Neurocognitive Impairment in Patients With HIV

More from this author
www.thecarlatreport.com
Issue Date: November 5, 2021
SUBSCRIBE NOW
Table Of Contents
How to Treat ADHD in Bipolar Disorder
In the News: Aducanumab (Aduhelm)
Viloxazine for ADHD
Listening to Depression: The Importance of Addressing Hearing Loss
Establishing a Dose-Response Relationship for Lurasidone in Acute Schizophrenia
Sleepwalking on Antipsychotics and Lithium
In Brief: Meds in the Fast Lane
How to Diagnose Bipolar Disorder
Nutritional Psychiatry in Practice
CME Post-Test - Bipolar Disorder, TCPR, November/December 2021
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.